Provided herein, among other things, are methods of administering NK cells comprising poly nucleotides comprising a nucleic acid encoding an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR).

The present disclosure relates to a nucleic acid molecule, a polypeptide, a protein, a cell, or a system comprising a cytokine, optionally a targeting moiety (e.g., a chimeric antigens receptor), and an anchoring structure that can attach to the surface of a cell (e.g., an engineered immune cell), and the methods to prepare the same and to use the same to treat a disease or a condition.

The present disclosure provides compositions of immune cells presenting a target molecule or a fragment thereof and provides compositions and methods of producing immune cell therapies with targeted activity against cancer. Methods for conditioning a subject receiving the immune cell therapy of the disclosure are additionally disclosed. The immune cell therapies of the present disclosure can be administered to a subject in need thereof for diseases such as cancer.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present invention relates to the combination therapy of recombinant Fc domain-IL-2 variant polypeptides with membrane-anchored antigen binding polypeptides in the prevention or treatment of cancer.

An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

Provided herein is a method of adoptive cell therapy. The method includes administering to a subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes. Also provided herein is a method of treating cancer in a subject by administering to the subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes.

Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.